UMIN-CTR Clinical Trial

UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials


Recruitment status Completed
Unique ID issued by UMIN UMIN000010138
Receipt No. R000011871
Scientific Title Prognostic evaluation for renal anemia patients on hemodialysis based upon hemoglobin levels during treatment with Epoetin Beta Pegol: multicenter prospective study
Date of disclosure of the study information 2013/03/01
Last modified on 2019/02/21

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments

Basic information
Public title Prognostic evaluation for renal anemia patients on hemodialysis based upon hemoglobin levels during treatment with Epoetin Beta Pegol: multicenter prospective study
Acronym PARAMOUNT-HD Study
Scientific Title Prognostic evaluation for renal anemia patients on hemodialysis based upon hemoglobin levels during treatment with Epoetin Beta Pegol: multicenter prospective study
Scientific Title:Acronym PARAMOUNT-HD Study

Condition Renal anemia on hemodialysis
Classification by specialty
Medicine in general Nephrology
Classification by malignancy Others
Genomic information NO

Narrative objectives1 To evaluate the prognoses by different target hemoglobin levels achieved by epoetin beta pegol dosing to renal anemia patients on hemodialysis who were poor responder to ESA.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1 Confirmatory
Trial characteristics_2 Pragmatic
Developmental phase Not applicable

Primary outcomes Cardiovascular prognosis(randomized study part)
Time to cardiovascular events such as cardiac death (death with heart failure, lethal myocardial infarction, sudden cardiac death), heart failure requiring hospitalization, and acute coronary syndrome (nonfatal myocardial infarction, unstable angina) requiring hospitalization.
Key secondary outcomes (randomized study part)
(1) Cardiovascular events
(2) Death
(3) Relationship between iron index and prognosis
(4) Quality of life
(5) Safety

Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Open -no one is blinded
Control Active
Stratification NO
Dynamic allocation YES
Institution consideration Institution is not considered as adjustment factor.
Blocking NO
Concealment Central registration

No. of arms 2
Purpose of intervention Treatment
Type of intervention
Interventions/Control_1 (randomized study part)
Active group:
Patients take epoetin beta pegol with the target hemoglobin level of 11 g/dL or more.
Maintenance group:
Patients take epoetin beta pegol to maintain their hemoglobin levels at 9-10 g/dL.
Interventions/Control_2 (randomized study part)
Maintenance group:
Patients take epoetin beta pegol to maintain their hemoglobin levels at 9-10 g/dL.

Age-lower limit
20 years-old <=
Age-upper limit
85 years-old >=
Gender Male and Female
Key inclusion criteria (randomized study part)
(1) Age >=20 and <=85 years at the time of giving informed consent
(2) Receiving drug therapy with ESA other
(3) More than one year after dialysis induction
(4) A poor responder to ESA without improvement of anemia after six month of ESA administration
(5) Without iron deficiency (100 serum ferritin>100 ng/mL or TSAT>20%)
(6) Gave written informed consent for participating in the randomized study participation by the patient himself/herself.
Key exclusion criteria (randomized study part)
(1) Anemia for other reasons than the renal anemia:
Complication of apparent hemorrhagic lesion, hematologic disease (e.g. leukemia, malignant lymphoma, myelodysplastic syndrome, aplastic anemia), or apparent chronic inflammation (e.g. rheumatoid arthritis, inflammatory bowel disease)
(2) Hypersensitivity to epoetin beta pegol, erythropoietin, or darbepoetin alfa
(3) Complication of malignant tumor
(4) Pregnancy, nursing or planning to become pregnant during the study (women only)
(5) Judged as ineligible to the randomized study in the opinion of the investigator
Target sample size 530

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Kosaku Nitta
Organization Tokyo Women's Medical University
Division name Department of Medicine
Zip code
Address 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan
TEL 03-3353-8111

Public contact
Name of contact person
1st name
Middle name
Last name Miiko Endo
Organization EP CRSU Co., Ltd.
Division name Clinical Research Promotion Dept.
Zip code
Address 6-29 Shinogawa-machi, Shinjyuku-ku, Tokyo, 162-0814
TEL 03-5842-7480
Homepage URL

Institute EP CRSU Co., Ltd.

Funding Source
Organization Chugai Pharmaceutical Co., Ltd.
Category of Funding Organization Profit organization
Nationality of Funding Organization Japan

Other related organizations
Name of secondary funder(s)

IRB Contact (For public release)

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2

Institutions 医療法人社団洛和会 洛和会音羽記念病院(京都府)、医療法人尚腎会 高知高須病院(高知県)、町立中標津病院(北海道)、医療法人社団養生館 苫小牧日翔病院(北海道)、医療法人社団石川記念会 新宿石川クリニック(東京都)、特定医療法人明仁会 明舞中央病院(兵庫県)、公益財団法人ときわ会 常磐病院(福島県)、 医療法人待望主会 安立医院(沖縄県)、医療法人財団博仁会 キナシ大林病院(香川県)、医療法人社団喜多町診療所(新潟県)、医療法人仁栄会 島津クリニック(高知県)、社会医療法人社団順江会 東京綾瀬腎クリニック(東京都)、医療法人社団英山会 平山泌尿器科医院(熊本県)、独立行政法人 地域医療機能推進機構 横浜中央病院(神奈川県)、医療法人 いぶきクリニック 分院(大阪府)、JA徳島厚生連 吉野川医療センター(徳島県)、医療法人社団日高会 平成日高クリニック(群馬県)、社会医療法人川島会 川島病院(徳島県)、こひつじ会グループ 医療法人社団小羊会 千葉横戸クリニック(千葉県)、社会医療法人信愛会 畷生会脳神経外科病院(大阪府)、こひつじ会グループ 医療法人社団小羊会 長沼クリニック(千葉県)、医療法人 中央内科クリニック(広島県)、医療法人社団玄成会 達内科(宮城県)、医療法人以和貴会 西崎病院(沖縄県)、岩見沢市立総合病院(北海道)、社会医療法人北楡会 札幌北楡病院(北海道)、医療法人青仁会 池田病院(鹿児島県)、医療法人社団明洋会 柴垣医院 戸越(東京都)、医療法人財団倉田会 えいじんクリニック(神奈川県)、医療法人知邑舎 メディカルサテライト岩倉(愛知県)、医療法人社団一陽会 一陽会クリニック(広島県)、医療法人明和会 たまき青空病院(徳島県)、医療法人社団恵仁会 三島外科胃腸クリニック(愛媛県)、医療法人親和会 天神クリニック(福岡県)、医療法人進和会 西2条腎泌尿器科病院(北海道)、JA北海道厚生連 旭川厚生病院(北海道)、日本赤十字社 旭川赤十字病院(北海道)、公益財団法人湯浅報恩会 寿泉堂クリニック(福島県)、医療法人翠悠会 翠悠会診療所(奈良県)、福島県厚生農業協同組合連合会 白河厚生総合病院(福島県)、医療法人社団 清和会 笠岡第一病院(岡山県)、医療法人社団 天成会 天野医院(静岡県)、一般財団法人 脳神経疾患研究所附属 総合南東北病院(福島県)、医療法人社団豊済会 下落合クリニック(東京都)、公益財団法人 東京都保健医療公社 大久保病院(東京都)、医療法人社団 菅沼会 腎内科クリニック世田谷(東京都)、社会医療法人愛仁会 千船腎臓透析クリニック(大阪府)、医療法人青松会 のへじクリニック(青森県)、医療法人社団秀佑会 東海病院(東京都)、前田記念腎研究所 茂原クリニック(千葉県)、国家公務員共済組合連合会 横浜栄共済病院(神奈川県)他376施設

Other administrative information
Date of disclosure of the study information
2013 Year 03 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

URL related to results and publications
Number of participants that the trial has enrolled
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Recruitment status Completed
Date of protocol fixation
2013 Year 01 Month 23 Day
Date of IRB
Anticipated trial start date
2013 Year 04 Month 01 Day
Last follow-up date
2018 Year 03 Month 31 Day
Date of closure to data entry
2018 Year 07 Month 01 Day
Date trial data considered complete
2018 Year 11 Month 30 Day
Date analysis concluded
2019 Year 12 Month 31 Day

Other related information PARAMOUNT-HD Study(randomized study part+observational study part) is a multicenter prospective study of 5,000 renal anemia patients on hemodialysis. The PARAMOUNT-HD study is planned as a comprehensive design to perform simultaneously progressing randomized controlled study for 530 patients who were poor EPA responders and an observational study for 4,470 patients.
Primary objective of the PARAMOUNT-HD study is to evaluate the relationship between prognosis and ESA response following epoetin beta pegol therapy in renal anemia patients on hemodialysis.

Management information
Registered date
2013 Year 02 Month 28 Day
Last modified on
2019 Year 02 Month 21 Day

Link to view the page

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name

Contact us.